Search Results
Your search for The ASCO matches 21410 pages
Showing 12501 - 12550AACR-NCI-EORTC: Noninvasive Computational Imaging Approach May Help Predict Response to Immunotherapy
A computational imaging-based signature of immune-cell infiltration in and around a tumor could predict patients’ responses to treatment with anti–programmed cell death protein 1/programmed death-ligand 1 (PD-1/PD-L1) immunotherapies, according to data from a study presented by Sun et...
AACR-NCI-EORTC: Colorectal Cancer Test Could Detect Early Cancer-Causing Genetic Biomarkers With High Degree of Sensitivity
An investigational test that screens for colorectal cancer could detect genetic mutations that are indicative of the disease with a high degree of sensitivity and specificity, according to results of a study presented by Powell et al at the AACR-NCI-EORTC International Conference on Molecular...
Charles F. von Gunten, MD, PhD, on Palliative Care in Oncology: A Fellows Curriculum
Charles F. von Gunten, MD, PhD, of OhioHealth, discusses an online curriculum that changed younger physicians’ use of palliative medicine in practice during the year after fellowship training (Abstract 202).
Eric Roeland, MD, on Symptom Management: Expert Perspective
Eric Roeland, MD, of the University of California, San Diego, summarizes key papers delivered at the Palliative Care Symposium on managing insomnia, fatigue, nausea, and the ways in which physical therapy and nausea can reduce the side effect burden.
FDA Approves Axicabtagene Ciloleucel for Large B-Cell Lymphoma
On October 18, 2017, the U.S. Food and Drug Administration (FDA) granted regular approval to axicabtagene ciloleucel (Yescarta) for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma...
Gary Gilliland, MD, PhD, Testifies Before Congress on NIH Funding System
Gary Gilliland, MD, PhD, President and Director of Fred Hutchinson Cancer Research Center, recently delivered the following testimony and answered questions from members of the House Appropriations Subcommittee on Labor, Health and Human Services, Education, and Related Agencies. His remarks...
AACR-NCI-EORTC: Tipifarnib Shows Durable Antitumor Activity in HRAS-Mutant Head and Neck Cancer
Preliminary results from a phase II open-label trial of tipifarnib, a farnesyltransferase inhibitor, in patients with HRAS-mutant head and neck squamous cell carcinoma (HNSCC) were presented by Alan L. Ho, MD, PhD, of Memorial Sloan Kettering Cancer Center, at the AACR-NCI-EORTC International...
AACR-NCI-EORTC: Tazemetostat as Treatment for Certain Pediatric Relapsed or Refractory Solid Tumors
Children with relapsed or refractory malignant rhabdoid tumors, epithelioid sarcomas, or poorly differentiated chordomas with a particular genetic defect tolerated treatment with the investigational drug tazemetostat well, and some had objective and durable responses, according to data from a phase ...
AACR-NCI-EORTC: Colorectal Cancers May Mutate to Escape Immune System Detection
Whole-exome sequencing revealed that colorectal cancers with high mutational load (microsatellite instability–high, or MSI-H) predominantly use “immunoediting” to escape immune surveillance, while colorectal cancers with low mutational load (microsatellite stable, or MSS) use...
AACR-NCI-EORTC: Gene Therapy Shows Early Efficacy Against Recurrent Brain Cancer
More than a quarter of patients with recurrent high-grade glioma treated with the retroviral vector Toca 511 (vocimagene amiretrorepvec) combined with Toca FC (an extended-release formulation of fluorocytosine, a prodrug of fluorouracil [5-FU]) were alive more than 3 years after...
New Biosimilar Educational Materials for Health-Care Professionals From the FDA
The U.S. Food and Drug Administration (FDA) has announced the release of new educational materials for health-care professionals about biosimilar and interchangeable products. The agency developed these educational materials to help increase understanding about these important new types of...
FDA Accepts sBLA for Nivolumab in Resected, High-Risk, Advanced Melanoma
On October 16, Bristol-Myers Squibb announced that the U.S. Food and Drug Administration (FDA) has accepted for priority review its supplemental Biologics License Application (sBLA) for nivolumab (Opdivo) to treat patients with melanoma who are at high risk of disease recurrence following complete...
Early Study Suggests Potential Role of Paclitaxel in Peripheral Neuropathy and Possible Preventive Measures
In discovering how certain chemotherapy drugs cause peripheral neuropathy, researchers at Dana-Farber Cancer Institute have found a potential approach to preventing this common and troublesome side effect of cancer treatment. Their findings were published by Pease-Raissi et al in Neuron. The...
FDA Approves Intravenous Rolapitant for Delayed Chemotherapy-Induced Nausea and Vomiting
On October 25, the U.S. Food and Drug Administration (FDA) approved intravenous (IV) rolapitant (Varubi) in combination with other antiemetic agents in adults for the prevention of delayed nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including,...
CELESTIAL Trial: Cabozantinib Meets Primary Endpoint of Overall Survival in Patients With Advanced Hepatocellular Carcinoma
On October 16, Exelixis announced that its global phase III CELESTIAL trial met its primary endpoint of overall survival, with cabozantinib (Cabometyx) providing a statistically significant and clinically meaningful improvement in median overall survival compared to placebo in patients with...
Potential Treatment of Chordoma With PI3K Inhibitors
Patients with chordoma—a rare bone cancer of the skull and spine—could be helped by existing treatments, suggest scientists from the Wellcome Trust Sanger Institute, University College London Cancer Institute, and the Royal National Orthopaedic Hospital NHS Trust. In the largest...
FDA Grants Priority Review for Olaparib in Metastatic Breast Cancer
On October 18, AstraZeneca and Merck & Co announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to a supplemental New Drug Application (sNDA) for the use of olaparib (Lynparza) tablets in patients with germline BRCA-mutated, HER2-negative...
2017 ASCO Palliative Care: Yoga Can Be an Effective Supportive Therapy for People With Lung Cancer and Their Caregivers
In a feasibility trial of people with advanced lung cancer receiving radiation therapy and their caregivers, yoga was beneficial to both parties. These findings will be presented by Milbury et al at the upcoming 2017 Palliative and Supportive Care in Oncology Symposium in San Diego (Abstract 125). ...
2017 ASCO Palliative Care: People With Leukemia and Their Oncologists Have Vastly Different Perceptions of Prognosis
A study of 100 people with acute myeloid leukemia (AML) receiving chemotherapy found that patient and physician perceptions of treatment risk and the likelihood of a cure varied widely. Overall, patients tended to overestimate both the risk of dying due to treatment and the likelihood of a cure....
Erratum: Adoptive Cell Therapy—Act 1: The Beginning
In the September 25, 2017, issue of The ASCO Post, page 1, the date of approval was cited incorrectly for the genetically engineered T-cell therapy tisagenlecleucel (Kymriah). The U.S. Food and Drug Administration approved tisagenlecleucel on August 30, 2017. The T-cell therapeutic is approved for...
Moffitt Cancer Center Holds Leadership Series in New York
Moffitt Cancer Center has made a lasting commitment to the prevention and cure of cancer, working fervently in the areas of patient care, research, and education to advance further in fighting this disease, according to Alan F. List, MD, Moffitt’s President and Chief Executive Officer. Dr. List,...
Leading Lymphoma Clinician, Researcher, and Mentor, Oliver ‘Ollie’ Press, MD, PhD, Dies at 65
In 1988, 38-year-old Rita Lawrence found herself in a desperate situation. The lymphoma she’d been battling had recurred after 2 years of remission. She’d endured multiple rounds of tough chemotherapy, but it couldn’t stave off the swiftly growing tumors. When she learned of a radioimmunotherapy...
2017 ASCO Palliative Care: Resilience Intervention Improves Quality of Life for Adolescents and Young Adults With Cancer
Although a cancer diagnosis is daunting at any age, adolescents and young adults (AYAs) with the disease often face unique challenges and are at risk for poor psychosocial outcomes than older patients. A randomized study investigating whether a brief, age-appropriate, skills-based intervention...
2017 ASCO Palliative Care: Patients With Advanced Cancer Prefer Oncologists Not Use Computers in the Exam Room
Although the use of electronic health records in oncology care has led to improved care for patients, results from a new study show that oncologists need to be cautious about using computers during exam room visits, especially for patients with advanced cancer. The randomized study compared...
Register for December 1 FDA Workshop on Cardiovascular Toxicities in Immunotherapy Trials
THE U.S. FOOD & DRUG ADMINISTRATION (FDA) and the Oncology Center of Excellence (OCE) will host a complimentary public workshop, Assessment of Cardiovascular Toxicities in Immuno-Oncology Trials, on December 1. ASCO is supporting the workshop with the American College of Cardiology (ACC), the...
For Your Patients: ASCO Answers Managing Cancer-Related Pain Booklet
ASCO’S BOOKLET on Managing Cancer-Related Pain helps you work together with your patients to develop an individualized plan for pain management before they start treatment. Patients and their caregivers will learn about the importance of pain relief, including its causes, how it is diagnosed, and...
Quality Training Program Now Accepting Applications for 2018; Courses to Be Held in Miami and Northern Virginia
Applications are now being accepted for ASCO’s Quality Training Program (QTP), a comprehensive program designed to train oncology health-care providers to investigate and implement data-driven quality improvement, as well as manage clinical and nonclinical processes and outcomes. The program...
Recommend an Early-Career Oncologist for ASCO’s 2018 Health Policy Fellowship
APPLICATIONS ARE now being accepted for ASCO’s 2018 Health Policy Fellowship program. The Health Policy Fellowship aims to provide oncology fellows and early-career physicians with the necessary skills to shape cancer policy and to help increase the involvement of ASCO members in policy, advocacy,...
Documentary Film Takes a Walk on the Wild Side With Oncology Pioneers
Oncology luminaries. Thought leaders. The soul of chemotherapy. These are just a few of the phrases used to describe Emil Frei, MD, FASCO, Emil J Freireich, MD, FASCO, James F. Holland, MD, FASCO, Georges Mathé, MD, and their historic contributions to the world of oncology. Inspired by these...
Funding the Future of Cancer Research Led by Women Making an Impact
WOMEN WHO CONQUER CANCER (WWCC) funds the promising careers of the best and brightest women researchers through the Conquer Cancer Foundation’s Young Investigator Award (YIA) program. Thanks to the generosity of supporters, five awards were granted in 2017. Right now, gifts to the WWCC Endowment...
ASCO University Offers New Course Covering Resource-Stratified Guidelines
ASCO has created a series of clinical practice guidelines to benefit clinicians, public health leaders, and policymakers in all resource settings. These resource-stratified guidelines help medical professionals outline appropriate methods of treatment and care based on the level of health-care...
Effectiveness of Sentinel Lymph Node Biopsy in Patients With Newly Diagnosed Melanoma
Research presented at the 9th World Congress of Melanoma supports the updated guideline recommendation that sentinel lymph node biopsy be performed in more patients newly diagnosed with melanoma, as it has the potential to save lives due to the information the procedure provides. This biopsy can...
Intratumoral Plasmid IL-12 With Electroporation in Stage III/IV Melanoma
OncoSec Medical Incorporated presented new clinical data on ImmunoPulse IL-12 (intratumoral pIL-12 [tavokinogene telseplasmid] with electroporation) at the 9th World Congress of Melanoma. “We are excited to share updated data from our phase II clinical monotherapy trial with ImmunoPulse ...
Axl Inhibitor BGB324 in Combination With Trametinib Plus Dabrafenib or Pembrolizumab in Advanced Melanoma
BerGenBio ASA announced that the randomized phase Ib/II clinical study of the Axl inhibitor BGB324 in combination with either the MAP kinase inhibitors trametinib (Mekinist) plus dabrafenib (Tafinlar) or the immune checkpoint inhibitor pembrolizumab (Keytruda) in patients with advanced melanoma is...
FDA Accepts sBLA for Durvalumab in Locally Advanced Unresectable NSCLC
On October 17, the U.S. Food and Drug Administration (FDA) has accepted a supplemental Biologics License Application (sBLA) for durvalumab (Imfinzi) for the treatment of patients with locally advanced (stage III) unresectable non–small cell lung cancer (NSCLC) whose disease has not progressed ...
FDA Awards Grants for Clinical Trials to Stimulate Product Development for Rare Diseases
THE U.S. FOOD and Drug Administration (FDA) has awarded numerous new clinical trial research grants, totaling more than $22 million over the next 4 years, to boost the development of products for patients with rare diseases. These new grants were awarded to principal investigators from academia and ...
Carfilzomib May Be a Strong Candidate for Salvage Therapy in Relapsed/Refractory Multiple Myeloma—but Questions Remain
WITH THE INCLUSION of proteasome inhibitors and immunomodulatory agents first into salvage and then as components of first-line, consolidation, and maintenance regimens, response rates, depth of response, and median progression-free and overall survival have all improved for patients suffering...
No Progression-Free Survival Benefit With First-Line Nivolumab vs Chemotherapy in Advanced PD-L1–Positive NSCLC
AS REPORTED BY David P. Carbone, MD, PhD, of The Ohio State University Comprehensive Cancer Center, Columbus, and colleagues in The New England Journal of Medicine, the phase III CheckMate 026 trial has shown no progression-free survival benefit for first-line nivolumab (Opdivo) vs platinum-based...
For HPV Vaccine to Have Optimal Impact, ‘Provider Hesitancy’ Must Be Overcome
Honoring National Cancer Institute researchers Douglas R. Lowy, MD, and John T. Schiller, PhD, with the Lasker-DeBakey Clinical Medical Research Award for advances in technology that enabled the development of human papillomavirus (HPV) vaccines to prevent cervical cancer and other tumors caused by ...
ASCO Clinical Practice Guideline Update on Antiemetics in Patients With Cancer
AS REPORTED BY Paul J. Hesketh, MD, of Lahey Hospital and Medical Center, Burlington, Massachusetts, and colleagues in the Journal of Clinical Oncology, ASCO has updated its clinical practice guideline on the use of antiemetics in patients with cancer.1 The update was based on an expert panel...
Edward E. Partridge, MD, Named Chief Medical Officer of Guideway Care
Edward E. Partridge, MD, has been named Chief Medical Officer of the Birmingham, Alabama–based Guideway Care, according to an announcement by Craig Parker, the company’s President and Chief Executive Officer. Dr. Partridge, a gynecologic oncologist, is highly regarded for his work to improve...
Julie R. Palmer, ScD, Honored With 2017 AACR Distinguished Lecture on Cancer Health Disparities
The American Association for Cancer Research (AACR) awarded Julie R. Palmer, ScD, the AACR Distinguished Lecture on the Science of Cancer Health Disparities, funded by Susan G. Komen. Dr. Palmer was recognized for her work as a cancer epidemiologist who has devoted most of her career to...
FDA Conducts Global Operation to Protect Consumers From Potentially Dangerous Prescription Drugs Sold Online
THE U.S. FOOD AND DRUG ADMINISTRATION (FDA), in partnership with international regulatory and law enforcement agencies, recently took action against more than 500 websites that illegally sell potentially dangerous, unapproved versions of prescription medicines, including opioids, antibiotics, and...
Howard A. Fine, MD, Wins NIH Director’s Pioneer Award
Neuro-oncologist Howard A. Fine, MD, of Weill Cornell Medicine and NewYork-Presbyterian, will receive a 5-year, $6 million National Institutes of Health (NIH) Director’s Pioneer Award for brain cancer research. The award will support Dr. Fine’s approach to modeling deadly brain cancers in the...
Breast Cancer Has Changed Me, But the Change Has Been Positive
I’ve always had dense breasts and avoided doing breast self-exams because I couldn’t tell if the lumpiness I was feeling was something serious or merely normal fibrous tissue. Instead I relied on my yearly mammogram to spot any early signs of cancer. Four years ago, I was once again relieved to...
Stalked by BRCA1: A Women Struggles to Survive the Same Disease That Killed Her Mother
No matter what a person does in life, for good and bad, his or her inherited genetic makeup follows along the way. Such was the case with British journalist Sarah Gabriel, who inherited the BRCA1 mutation from her mother, who died of ovarian cancer when Ms. Gabriel was in college. Much of her...
Alectinib Yields Favorable Results in Phase III Trials of ALK-Positive NSCLC
RESULTS OF TWO separate phase III trials confirm the activity of alectinib (Alecensa) in the central nervous system (CNS) in patients with anaplastic lymphoma kinase (ALK)-positive non–small cell lung cancer (NSCLC). Results lend support for alectinib as the better first-line treatment option over...
Abiraterone or Docetaxel: Which Is Optimal for Hormone-Sensitive High-Risk Prostate Cancer?
ABIRATERONE ACETATE (Zytiga) plus prednisone and docetaxel have moved up from the castrate-resistant metastatic setting to earlier in the course of disease as treatment of high-risk hormone-sensitive prostate cancer in men who are initiating androgen-deprivation therapy, based on level 1 evidence...
Patient-Physician Communication and Quality of Life Featured at 2017 Palliative and Supportive Care in Oncology Symposium
NEW RESEARCH examining patient-physician communication, yoga as supportive care, and psychosocial support for people with cancer will be featured at the 2017 Palliative and Supportive Care in Oncology Symposium on October 27–28, 2017, in San Diego. Featured sessions include randomized trials on...
ASCO Recognizes New Jersey Representative Leonard Lance With Congressional Leadership Award
ASCO HAS PRESENTED Representative Leonard Lance, of New Jersey’s 7th district, with its second annual Congressional Leadership Award in recognition of the lawmaker’s exceptional commitment to supporting cancer research and treatment. ASCO President Dr. Bruce Johnson presented the award to...
